A Phase 1/2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose
expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer
(NSCLC) patients who have progressed following prior therapy with an epidermal growth factor
receptor(EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate
safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally
(PO) administered HS-10296. The overall study design is shown in the flow chart below, which
consists of 3 phases: dose escalation, dose expansion and extension cohort.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.